CN111440774A - Construction method of IFNGR2 gene melanoma B-16 cell line for stably expressing knock-in EGFP - Google Patents

Construction method of IFNGR2 gene melanoma B-16 cell line for stably expressing knock-in EGFP Download PDF

Info

Publication number
CN111440774A
CN111440774A CN202010332139.1A CN202010332139A CN111440774A CN 111440774 A CN111440774 A CN 111440774A CN 202010332139 A CN202010332139 A CN 202010332139A CN 111440774 A CN111440774 A CN 111440774A
Authority
CN
China
Prior art keywords
ifngr2
seq
gene
cell line
cris
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202010332139.1A
Other languages
Chinese (zh)
Inventor
李卫华
樊浩
周涛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomedical Analysis Center of AMMS
Original Assignee
Biomedical Analysis Center of AMMS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomedical Analysis Center of AMMS filed Critical Biomedical Analysis Center of AMMS
Priority to CN202010332139.1A priority Critical patent/CN111440774A/en
Publication of CN111440774A publication Critical patent/CN111440774A/en
Pending legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43595Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from coelenteratae, e.g. medusae
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7156Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interferons [IFN]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90Stable introduction of foreign DNA into chromosome
    • C12N15/902Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/20Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/10Screening for compounds of potential therapeutic value involving cells

Abstract

The invention discloses a construction method of an IFNGR2 gene melanoma B-16 cell line stably expressing knock-in EGFP. According to the invention, a green fluorescent protein EGFP gene sequence is knocked into the end of the last exon of an IFNGR2 gene in a cell, so that the EGFP gene sequence and the IFNGR2 gene are subjected to fusion expression. The result shows that the positive correlation between the EGFP fluorescence intensity and the IFNGR2 expression level can indicate the expression level of IFNGR2, and the cell line can be used for the IFNGR2 expression regulation research. The invention provides a powerful tool for finding the expression regulatory factor of IFNGR2 and screening the drug targeting tumor immunity.

Description

Construction method of IFNGR2 gene melanoma B-16 cell line for stably expressing knock-in EGFP
Technical Field
The invention relates to a construction method of an IFNGR2 gene melanoma B-16 cell line stably expressing knock-in EGFP.
Background
Tumor immunotherapy refers to a therapeutic method for targeting and attacking tumor cells by activating the inherent ability of the body's immune system, so as to control the development of tumors and kill tumors. The tumor immunotherapy mainly includes immune vaccine, immune checkpoint inhibitor therapy, adoptive immune cell therapy, cytokine therapy, and the like, in which the immune checkpoint inhibitor therapy is spotlighted with its remarkable clinical efficacy. However, current clinical trial data show that immune checkpoint inhibitors are effective in only about 20% of patients, and the causes and mechanisms leading to treatment failure have not been fully elucidated.
Gao J, et al, found that the lack of IFN γ signaling pathway in tumor cells resulted in drug tolerance of tumor cells, thereby resulting in failure of anti-CT L A4 therapy, Benci J L, et al, found that IFN γ signaling pathway could regulate the sensitivity of tumor cells to drugs at immune checkpoint.
IFN gamma through with cell membrane receptor binding, activation of Janus kinase/signal transduction and transcriptional activator (JAK/STAT) signal pathway, phosphorylated STAT nuclear and then regulation of interferon inducible gene expression. The interferon gamma receptor (IFN γ R) comprises two distinct subunits, IFNGR1 and IFNGR2, respectively. Studies have shown that cell surface IFNGR1 expression is excessive, but that IFNGR2 expression is tightly regulated, the amount of expression determining the responsiveness of the cell to IFN γ signaling. The elucidation of the expression regulation mechanism of IFNGR2 helps to elucidate the regulation mode and mechanism of the IFN gamma signal pathway, thereby providing a new strategy for improving the immunotherapy effect of tumors.
Disclosure of Invention
The invention aims to provide a construction method of an IFNGR2 gene melanoma B-16 cell line stably expressing knock-in EGFP.
In a first aspect, the present invention provides a method for preparing a cell line, comprising the steps of: performing gene editing on a B-16 melanoma cell by using a CRIS-PITCh system, inserting a coding gene of green fluorescent protein EGFP into the seventh exon end of IFNGR2 gene in the B-16 melanoma cell, and performing fusion expression on the coding gene of the green fluorescent protein EGFP and the IFNGR2 gene; the CRIS-PITCh system comprises a sgRNA expression cassette; the target sequence of the sgRNA is (a1) or (a2) as follows:
(a1) position 15884 and 15903 from the 5' end of SEQ ID NO. 1;
(a2) SEQ ID NO.1 at position 15939-15958 from the 5' end.
The CRIS-PITCh system comprises a carrier A and a carrier B; the vector A comprises a Cas9 expression cassette, an sgRNA expression cassette and a PITCh sgRNA expression cassette; the vector B comprises a donor fragment and homologous arms positioned at two ends of the donor fragment; the donor fragment is (b1) or (b2) as follows:
(b1) position 1595 and 2974 from the 5' end of SEQ ID NO. 4;
(b2) SEQ ID NO.5 positions 28 to 1407 from the 5' end.
The homology arms at both ends of the donor fragment described in (b1) are the upstream homology arm shown in position 1567-1586 from the 5 'end of SEQ ID NO.4 and the downstream homology arm shown in position 2975-2994 from the 5' end of SEQ ID NO. 4.
The homology arms at both ends of the donor fragment of (b2) are the upstream homology arm shown in SEQ ID NO.5 at 1-20 from the 5 'end and the downstream homology arm shown in SEQ ID NO.5 at 1408-1427 from the 5' end.
The CRIS-PITCh system can be composed of a circular plasmid (vector A) shown by SEQ ID NO.2 and a circular plasmid (vector B) shown by SEQ ID NO. 4.
The CRIS-PITCh system can also be composed of a circular plasmid (vector A) obtained by replacing 8319-8343 positions from the 5 'end of SEQ ID NO.2 with SEQ ID NO.3 and a circular plasmid (vector B) obtained by replacing 1567-2994 positions from the 5' end of SEQ ID NO.4 with SEQ ID NO. 5.
In a second aspect, the invention provides a cell line produced by the method of the first aspect.
In the examples of the present invention, two cell lines were prepared by the above-described method.
One of these differs from the wild type (B-16 melanoma cells) in that: the DNA molecule shown in the 15886 and 15887 positions from the 5 'end of SEQ ID NO.4 is inserted between the 15886 and 15887 positions from the 5' end of SEQ ID NO. 1. Another difference from the wild type is that: the DNA molecule shown in SEQ ID NO.5 from positions 21 to 1407 of the 5 'end is inserted between positions 15941 and 15942 of the 5' end of SEQ ID NO. 1.
In a third aspect, the invention protects the application of the cell line in the research of IFNGR2 gene function and expression regulation mechanism.
The invention also protects the application of the cell line in the screening of the medicine for targeting tumor immunity.
In a fourth aspect, the invention protects the sgRNA expression cassette or the CRIS-PITCh system described in any of the preceding paragraphs.
In a fifth aspect, the invention protects the use of the sgRNA expression cassette or the CRIS-PITCh system described in any of the above in the preparation of the cell line described above.
The invention also protects the application of the sgRNA expression cassette or the CRIS-PITCh system in researching IFNGR2 gene function and expression regulation mechanism or tumor immunity targeted drug screening.
The invention also protects the application of the sgRNA expression cassette or the CRIS-PITCh system in the preparation of a cell line for researching IFNGR2 gene function and expression regulation mechanism or drug screening of targeted tumor immunity.
Any one of the IFNGR2 genes is a DNA molecule shown in SEQ ID NO. 1.
Any of the IFNGR2 genes is a DNA molecule which has 90 percent of homology with SEQ ID NO.1 and has the same function.
According to the invention, a green fluorescent protein EGFP gene sequence is knocked into the end of the last exon of an IFNGR2 gene in a cell, so that the EGFP gene sequence and the IFNGR2 gene are subjected to fusion expression. The result shows that the positive correlation between the EGFP fluorescence intensity and the IFNGR2 expression level can indicate the expression level of IFNGR2, and the cell line can be used for the IFNGR2 expression regulation research. The invention provides a powerful tool for finding the expression regulatory factor of IFNGR2 and screening the drug targeting tumor immunity.
Drawings
FIG. 1 is a design and flow chart of an IFNGR2 insertion site; (a) the target site of gene editing is located at the end of the last exon, and the donor vector comprises EGFP sequence (b) design of mouse Ifngr2 gene insertion site (c) gene editing flow diagram.
FIG. 2 is a schematic diagram of CRISPR-Cas9 and CRIS-PITCH (v2) vector construction; (a) schematic diagram of CRISPR-Cas9 construction; (b) CRIS-PITCH (v2) construction scheme.
FIG. 3 is a drawing of the identification of IFNGR2-EGFP cell line (a) genomic PCR identification primer design; (b) and (c) identifying the electrophoresis result map by genome PCR, wherein an arrow points to a target band; (d) and (e) product 1 sequencing results plot, blue part is homology arm sequence; (f) flow chart of positive clones, positive cells in box; (g) the fluorescence microscope showed that the positive clones showed green fluorescence.
Figure 4 shows that positive clones were normal for IFN γ reactivity, (a) the relative expression of Cd274 (PD-L1) was up-regulated (b) the relative expression of Psmb9 was up-regulated, n-3, p <0.001, p <0.01, p < 0.05.
FIG. 5 shows that TNF- α and oxaliplatin up-regulate the expression of Ifngr2 and EGFP, (a) and (e) after stimulation of TNF- α and oxaliplatin, green fluorescence right shift oxal: oxaliplatin, (b) and (f) flow observation result statistical graphs, (c), (d), (g), (h), (i) and (j) qPCR analysis results under different stimulations, TNF- α and oxaliplatin stimulation up-regulate the relative expression of Ifngr2 and EGFPMRNA, and IFN gamma cannot up-regulate the relative expression of Ifngr2 and EGFP mRNA.
Detailed Description
The following examples are given to facilitate a better understanding of the invention, but do not limit the invention. The experimental procedures in the following examples are conventional unless otherwise specified. The test materials used in the following examples were purchased from a conventional biochemical reagent store unless otherwise specified. The quantitative tests in the following examples, all set up three replicates and the results averaged. Statistical analyses in the following examples were performed using GraphPad Prism software, where differences between groups were analyzed using the t-test, and P <0.05 considered statistically significant.
The embodiment of the invention carries out gene editing by using a CRIS-PITCh system, and knocks a green fluorescent protein EGFP gene sequence into the end of the last exon of an IFNGR2 gene in a B-16 melanoma cell, so that the EGFP gene sequence and the IFNGR2 gene are fused and expressed. The experimental design concept and flow are shown in fig. 1.
The IFNGR2 gene is shown in SEQ ID NO. 1. In SEQ ID NO.1, the 15814-15948 th exon from the 5' end is the seventh exon.
Example 1 sgRNA target selection and oligonucleotide strand synthesis thereof
IFNGR2 gene sequence was analyzed, and guideRNA was designed using http:// chopchop. Two sites were selected from several sites and named PAM1 and PAM2, respectively.
The primer sequences were synthesized by Biotechnology engineering, Inc., as shown in Table 1 below.
TABLE 1
Figure BDA0002465336860000031
In Table 1, underlined sequences are target sequences.
Example 2 construction of Gene editing vectors
Two vectors, CRISPR-Cas9 vector and CRIS-PITCH (V2) vector, are required for microhomologous end-joining gene knock-in. The main structure and construction process of the vector are shown in FIG. 2. Wherein the CRISPR-Cas9 vector comprises a knock-in position sgRNA expression cassette and a PITCh sgRNA expression cassette for making DNA double strand breaks of the genomic and donor vectors. CRIS-PITCH (V2) is a donor vector, comprises a DNA fragment to be inserted into a genome, EGFP and puromycin resistance genes separated by a 2A sequence, homologous sequences at two ends of the fragment are at two sides of an editing position, and an upstream homologous arm and a downstream homologous arm are both about 20 bp.
Construction of CRISPR-Cas9 vector
CRIPSR-Cas9-PAM1 vector at PAM1 site and CRIPSR-Cas9-PAM2 vector at PAM2 site were constructed by referring to the following steps, respectively.
1. The upstream and downstream primers in Table 1 were annealed to form double-stranded DNA molecules.
2. After digestion of the pX330A-1X2 plasmid (purchased from Addgene) with BbsI, the cleavage product (about 8941bp) was recovered from the gel.
3. And (3) connecting the double-stranded DNA molecule prepared in the step (1) with the plasmid enzyme digestion product prepared in the step (2) by adopting T4 DNA ligase to obtain a pX330-1x2-sgRNA recombinant plasmid.
4. The pX330-1x2-sgRNA recombinant plasmid was digested with BsaI, and the digestion product (about 8471bp) was recovered from the gel.
5. After digestion of the pX330S-2-PITCh plasmid (purchased from Addgene) with BsaI, the digestion product (ca.443 bp) was recovered from the gel.
6. And (3) connecting the enzyme-cut product prepared in the step (4) with the enzyme-cut product prepared in the step (5) by using T4 DNA ligase to obtain a CRISPR-Cas9 vector.
The CRIPSR-Cas9-PAM1 vector is a circular plasmid shown as SEQ ID NO. 2.
The CRIPSR-Cas9-PAM2 is a circular plasmid obtained by replacing the 8319-8343 position from the 5' end of SEQ ID NO.2 with the SEQ ID NO. 3.
Construction of the second, CRIS-PITCH (V2) vector
1. Primers respectively containing sequences at the upstream and downstream of the PITCh gRNA, IFNGR2-PAM1 and IFNGR2-PAM2 sites are designed, and the specific details are shown in Table 2.
TABLE 2
Figure BDA0002465336860000041
2. PCR amplification was performed using a PCR amplification primer using a PCRIS-PITCH (V2) -FB L vector (purchased from Addgene) as a template, and the amplification products (about 1500bp EGFP-2A-Puro fragment containing the homology arm of the target gene and 4500bp vector backbone fragment) were separated and purified by agarose gel electrophoresis.
3. And (3) recombining and connecting the purified product obtained in the step (2) by using ExnaseII recombinase to obtain CRIS-PITCh (v2) -PAM1 and CRIS-PITCh (v2) -PAM2 vectors.
The CRIS-PITCh (v2) -PAM1 vector is a circular plasmid shown in SEQ ID NO. 4. In SEQ ID NO.4, the position 1567-1586 from the 5' end is an upstream homology arm, the position 1595-2974 is a donor fragment (wherein the position 1595-2311 is an EGFP gene sequence, the position 2312-2374 is a T2A spacer sequence, the position 2375-2974 is a Puro sequence), and the position 2975-2994 is a downstream homology arm.
The CRIS-PITCh (v2) -PAM2 vector is a circular plasmid obtained by replacing position 1567-2994 from the 5' end of SEQ ID NO.4 with SEQ ID NO. 5. In SEQ ID NO.5, the upstream homology arm is located at positions 1-20 from the 5' end, the donor fragment is located at positions 28-1407 (wherein positions 28-744 are the EGFP gene sequence, positions 745-807 are the T2A spacer sequence, positions 808-1407 are the Puro sequence), and positions 1408-1427 are the downstream homology arm.
Example 3 establishment of melanoma B-16 cell line stably expressing IFNGR2 Gene knock-in EGFP
First, establishment of cell line
1. The B-16 melanoma cell line (ATCC, accession No.:
Figure BDA0002465336860000042
CRL-6475TM) Inoculating into 6-well plate, culturing in 1640 medium containing 10% fetal calf serum at 37 deg.C and 5% CO2Culturing under the condition until the cell density reaches 60-80%.
2. After completion of step 1, transfection procedures were performed using plasmid transfection reagents L ipofectamine (TM) L TX (Invitrogen) according to the instructions, and plasmids of group 1(CRIPSR-Cas9-PAM1 vector and CRIS-PITCh (v2) -PAM1 vector) and group 2(CRIPSR-Cas9-PAM1 vector and CRIS-PITCh (v2) -PAM1 vector, in a ratio of 2:1) were transfected into cells, respectively, and a group transfected with pmCherry-C1 plasmid (purchased from Addge) was set as a positive control.
The procedure was to mix the plasmid and transfection reagent in 150. mu.l: standing for 15min after 6 mul is uniformly mixed, then dropwise adding the mixture into cells, absorbing and removing culture solution after 6h of transfection, adding fresh culture solution and continuously culturing overnight, and observing the fluorescence condition of a positive control group under a fluorescence microscope after 24h of transfection to confirm the transfection effect; cells were transferred from six-well plates to 10cm dishes 72h after transfection, the medium was replaced with puromycin (2mg/ml) containing medium and the medium was changed every three days until a monoclonal cell mass grew in the dish. And (3) picking the monoclonal cell clusters to a 96-well plate under a microscope for continuous culture, transferring the cells to a 6-well plate for continuous culture after the cells grow full, and performing subsequent identification.
Cells were first identified by PCR, and the primers used for PCR are shown in Table 3.
In Table 3, primer pair 1 and primer pair 2 were used to identify positive clones of group 1 (i.e., transformed into CRIPSR-Cas9-PAM1 vector); primer pair 1 and primer pair 3 were used to identify positive clones of group 2 (i.e., transformed into CRIPSR-Cas9-PAM2 vector). A schematic of the amplified region of the primer pair is shown in FIG. 3 a.
Amplification using primer pair 1 should yield product 1 with a molecular weight of about 500 bp.
Amplification using primer pair 2 should yield product 2 of approximately 1450bp in size.
Amplification using primer pair 3 should yield a product 3 of approximately 1450bp in size.
TABLE 3
Figure BDA0002465336860000051
Genomic DNA of the cells was extracted and PCR amplified using the primers shown in Table 2, respectively.
The PCR results of one positive clone E10 selected from group 1 (i.e., transformed into CRIPSR-Cas9-PAM1 vector) and one positive clone B4 selected from group 2 (i.e., transformed into CRIPSR-Cas9-PAM2 vector) are shown in FIG. 3B and FIG. 3 c.
The product 1 of both clones was purified and sequenced, and the alignment results are shown in fig. 3d and fig. 3e, indicating successful insertion of the EGFP sequence into the genomic target site.
The positive clone E10 was sequenced and distinguished from the wild type by: the DNA molecule shown in the 15886 and 15887 positions from the 5 'end of SEQ ID NO.4 is inserted between the 15886 and 15887 positions from the 5' end of SEQ ID NO. 1. The positive clone B4 differs from the wild type in that: the DNA molecule shown in SEQ ID NO.5 from positions 21 to 1407 of the 5 'end is inserted between positions 15941 and 15942 of the 5' end of SEQ ID NO. 1.
Flow analysis was performed for E10 and B4, respectively, and fluorescence expression intensity of EGFP was observed using a living cell imaging system (DV). The B-16 melanoma cell line was used as a control.
The flow results are shown in fig. 3f, the green fluorescence intensity of the positive cell line is significantly higher than that of the control group, and the positive rate reaches more than 95%. The fluorescence observation results are shown in fig. 3g, and green fluorescence can be successfully observed in the positive cell line, but cannot be observed in the control group, indicating that the inserted EGFP sequence is successfully expressed.
30 clones are respectively picked from PAM1 and PAM2 for identification, 7 positive clones are identified by PAM1, the positive rate is about 23.3 percent, 1 positive clone is identified by PAM2, and the positive rate is 3.3 percent.
Example 4 detection of cell lines
1. Clones E10 and B4 prepared in the examples were inoculated in 6-well plates using 1640 medium containing 10% fetal bovine serum at 37 ℃ with 5% CO2Culturing under the condition until the cell density reaches 60-80%.
2. After completion of step 1, samples were collected simultaneously with the solvent control group for the same time after 48H of treatment with IFN γ (R & D485-MI-100) (20ng/ml), 48H of treatment with Oxaliplatin (Oxaliplatin for injection, Nanjing pharmaceutical factory Co., Ltd., national drug Standard H20000686) (2. mu. mol/ml) and 3H of treatment with TNF- α (R & D Systems, 410-MT-010/CF) (20ng/ml), respectively.
3. Extracting the total RNA of the cells collected in the step 2 and performing reverse transcription to obtain cDNA. The cDNA was used as a template for real-time quantitative PCR detection, and the primers for detection are shown in Table 6. Each group was repeated 3 times, and relative expression amounts and fold differences were calculated using GAPDH as an internal reference gene and subjected to statistical analysis.
TABLE 6
Figure BDA0002465336860000061
To determine whether the B16-IFNGR2I-EGFP cell line can respond to the stimulation of IFN gamma, IFN gamma treatment is carried out on positive clones, and the expression of downstream target genes Cd274(PD L1) and Psmb9 of the IFN gamma is detected, the result is shown in figure 4, the result shows that the expression of Cd274(PD L1) and Psmb9 is remarkably up-regulated 48 hours after the stimulation of the IFN gamma (20ng/ml), and the up-regulated amplitude is equivalent to that of the parent cell B-16, which indicates that the two cells can respond to the stimulation of the IFN gamma, and indicates that the IFN gamma signal channel in the cells is complete.
Flow cytometry analysis was performed on cell clones E10 and B4 after stimulation with TNF- α and oxalliplatin, respectively, and RNA was simultaneously extracted for qPCR analysis, flow results are shown in fig. 5a and 5E, and after treatment with TNF- α and oxalliplatin, the green fluorescence peaks in positive clones E10 and B4 cell lines shifted to the right, indicating increased EGFP expression, the mean fluorescence intensity values of the main cell population were calculated and statistically analyzed, showing that TNF- α and oxalliplatin treatment significantly enhanced fluorescence of E10 and B4 cells (fig. 5B, f), qPCR analysis shows that TNF- α and oxalliplatin treatment significantly increased both IRNGR2 and EGFP mRNA levels in E10 and B4 cells at the same time, the above results show that the intensity of green fluorescence in B16-IRNGR2-GFP cells can reflect the expression level of IRNGR2 in cells.
Sequence listing
<110> biomedical analysis center of military medical research institute of military science institute
<120> construction method of IFNGR2 gene melanoma B-16 cell line stably expressing knock-in EGFP
<160>5
<170>SIPOSequenceListing 1.0
<210>1
<211>16950
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>1
ggctctgcgg ctaggctggg gaagaggcgg gcgctcggct cgccatggcc gctgcggtgc 60
gagtctgagc ggcgtccacc ccgcggtccc gggccgcccg ggccatgcgg cctttgccac 120
tgtggctgcc gtcgctgctg ctctgtgggc tcggtgccgc ggcgtcctcg ccaggtaagc 180
gcgacccagg agacccccca ccccaccccc gactcctcgg gctctcctgg gtgtcgcgtc 240
cgcgcgtggg tggctccggg agcttgcacc cggcacaggg tggggttctg cagtcgttcc 300
cgatctgcgg gtgaccgcga tcggacgggg caccgaccag gaggaatctg caagagggag 360
ctgcagtgag tgtagcgtgg accacgggga attccaggcc tggaggtgga gagcccagtt 420
cgtctttggc tccttggtgc cagggagatc agctgacggg caggaccagt atttgtctgg 480
gcagcctata aaatcctcgt actcagttcc tcgggatctt atagatgggg agcagaaatg 540
cctgtgtccc ctccagtgta tggggacaga gggtcagctg aggcacactt ttaatctcag 600
ctctatccta ctccgcccac acagcccttt accggggttc aacttcccac ttttgtcacc 660
aacctgactg tatttatgag ccagtcatca aaaccaacaa aagaaagaca tcactaacca 720
agaacattct tcctacgtga ttatattttg ctgggttctt tcccgtgcag agatcatatc 780
aaagcttgga tatctggagt ccacagtggt agtggggtgc acccttgtga aaacacagaa 840
ctcaggatga gaaaaagggg tcctgaagtt tctggccggc cgggccggct tggtttactc 900
agtgggtctt gctgttgttg tttattttgt tttttttata gtttggccat tagttaaata 960
agcctacgaa ttgggacgtt ccctcccatt ggaagtggtg ttgaggagtt agttggtcct 1020
ctgtcagcat ccctgcaaag gcccttaagt tccctttctc cttaagggca gaggagcaca 1080
ggaggatgag tgggttacgc agttaacttg ttctcctgga gtcagacaaa gactttaaac 1140
cctggctctg atgttcccca ttttgccttg agcaatctgt gtctgacaca cccacacaca 1200
caggtctcct ttggaggaga gcctgcgatt gtctgagatg tctgtgaact atgtgttcag 1260
aagttgatag gcgtatttag aaactttaca acagacattt ttctaatgat taacttttta 1320
ttatgctcca caaaagtcgt ggtctgtggc tcattaacaa caaattggat ccttagatat 1380
tttgaaaatg gtagcctttt gtaaatttct tagactctca tgccactctt aacgcgaaat 1440
tttcacactt tttttttaaa agaaaaacta ggatatgttt aaaagaaacc cttttagtca 1500
cagtgcagag tgaaaatatt gacattgttc ttgcggccaa caggtaatga gaagattccc 1560
ataactgttc cataggttat gaatggccct caggaatcat aaaattgctt ttaacaacat 1620
attcatgttt tgcctgcatg tctatgtatg tctatgcacc acttgagttc ctggtgctta 1680
cggaagccaa aagaggccat catatctccc agaactggag ctataaatag ttctgagctg 1740
ccctgctggg gctagaactc taatagagta gcaagtgccc ttaaccaccg ggccatctca 1800
cagccccgga aacaaggctt tgaaaggaac atttgtaaaa cgctccaggg agtcaaggct 1860
agcatatcaa tactgtaccc caaacaggct ggagttactc tctgttgctt tgttaggtgg 1920
cagccatttg ctgtagatca taaaaacaaa acaaaaaaga ataattgata gcatgagact 1980
ctttagttat tcagtttcct gcacagaagg atcaaggctt ctgcttgtag ccatggctgc 2040
tctttgtact gtggagtagc cgtgtgtgag catgtgagtg tgtgcgtgta tgtgtgtgtc 2100
tgtgtgtatg tctctctgta tgcaactcta tgtgtgtgtg tctctatgtg tctgtgtgtg 2160
catgtgtgtc tctgtgtgta actctgtgtg tctctatgta tctgtatgtg tgtctgtgag 2220
tgtatgtgtg catgtgtgtc tctgtgtgtg taactgtgtg tgtgtctatg tgtctgtgag 2280
tgtatatgtg tgtgtgtgtc tctgtgtctg tgtgtaactc tgtgtgtgtg tgtgtgtcta 2340
tgtatctgtg tatgtgtgta tgtgtgtgtt tgaaggaata tccaaaccaa tgggtgttag 2400
ggaatttcct gtttgggtgt tgtctcttca ggtggaactg tcttgtaatt ggataggtga 2460
taatcctagc tcccatttat tgagacaagc tgctaagggc tgtgtgtatt ttctctctct 2520
ctctctctct tttgtttttg tttttgtttt tgtttttcgt gacagcgttt ctctgtatat 2580
ccctggctgt catggaactc actttgtaga tcaggctggc ctcgaactca gaaatccacc 2640
tgcctctatt ttctctcttt taatcttcat attttactgc caggaagaga caaatgatct 2700
agggagaaaa aaaaaaccca cttgctgtgg ggatttacta aaaagaatca cttcctggtt 2760
ctgactgaag ggtgaggact gtttatttcc ctgtcacatt taagttgctg gaggtgaggt 2820
cattggtgtc aggtctaatt catgtgaggc tgaccaagag gcatagagag aggctagaac 2880
cagggagtgg gtatagcctt caaagacctg tctctgccga tctgttcctt cacgcaggcc 2940
ctgcacttac aggctccaca gccctcaaaa tagcctcaca ggctggagac ccggtattca 3000
aagcctgtgg gggacctgtc agcccctaac aataatgaga ctcccaccag gccgcagtat 3060
ttgctgtcgg ataaagggcc tcacttgtct ggaatcctgc cttgagccac aggatcccgt 3120
aagcccccac ctgggcctcg gttccctcat aaagaacaga acttcttccc atagagctgt 3180
gagaggcaaa cccaagatcc gaagtaaaaa gcaaagctga ggagatagct aggcagtggt 3240
gactacgagc actcactgct cctgcagagg tctggggttt ggttcccagc gcccacccac 3300
ccacgtaaga tgctgtctgc cctcctggca cctgcaagca catgggacac atagccacac 3360
ccacatacac ataaataatg aggcgaaagg gccaaaccag acagcataat ctgtcttttg 3420
tttttgtttt taaagatgtg attagttggg ggtctttggt tttttttttt tttttttttc 3480
ttttggatgg tgagatagat gcttgctgcc aaggctagtg acttaactct gaaatctagg 3540
atctgcagga gagaactgac ttccacaagt tgttctctgt ctctgtctct gtctctgtct 3600
ctgtctctct ctctctctct ctctctctct ctctctctct cacacacaca cacacacaca 3660
caaattaaga aaagatgtca cggggctggt gagatggctc agtgggtaag agcacccgac 3720
tgctcttccg aaggttcaga gttcaaatcc cagcaaccac atggtggctc acaaccatct 3780
ttaacaagat ctgactccct cttctggatt ggtctgaaga cagctacagt gtacttacat 3840
ataataaata aatgaatctt taaaaaaaaa aaaaaaaaaa aaaagaaaag atgtcacatt 3900
taagatgtgg ctgtttctta gttcctggtt cccatggctg ccttgcaggt aatgagagct 3960
ggttccagag acagctcgtt ggcacagtat tcaatggctc cgtcctgtca cagattagcc 4020
tgccttcttc ctcgagatgc ctgtgtttgt gactgttagg ttacatgaga agcggcaggt 4080
tcctagtcag acggtcttaa aactggcagt ctattttggc atatctgggt tgtgtccagt 4140
ataatcacaa gggaggtggt ttcaggacaa tctagccagg gtagggttct tccacctgca 4200
gctcctagga ccacggcctt tgctcttgaa acagctgcct ctctggccgg gagcactgta 4260
tctcctatgg gggcaaaagc tcccagaccc caggggagtg tgcaaagctc ctcctttctc 4320
cgtgcgcctg tggcctctga gtcacgaacc actaatgata agagctgggt gtagcctgtt 4380
tgaacgctcc ctgcacctca gccctgtaca ggtccctcca tcctgccctt cctgcttcac 4440
ccgtgatgtg cctggggtag agacacttga gacttgatag attcttcaga ctaggtcagg 4500
tgtgcagcca cacagtccag cgccaatggc agtgtcccca tatgcctgcc ttccccgtta 4560
gcacggactg gaatccagtg cattctgtca ggcagtttgg tcccagggac acaaaagtaa 4620
caggggtctt tagaaccatc cggagaaggt cagcacccct gccctggcct gtgacacgag 4680
acaaaaccac aggccaaaca caaagcaagg aagagagcgc ctgggccttg agtgggttct 4740
gttccatttt tttttttcat ggttaacagc agtctgtcag cgcaatgttc gttctccgca 4800
tcttctgagc ctgctgttcc aggcccagag agaaagcacc cctgaatccc gcagcacctc 4860
agcttctcaa agtgtctgcg tggcgctgaa gagtaactga tgggcagctg tgggaaaaaa 4920
aatgtgagct gagcctacac agcacacaaa gtcgctcctt ccacagaaag actgtgttga 4980
ggacggacgc actgtgactg gtctccagac ccaaatacct tatccagagg caagcacaaa 5040
gacagtagca gaggagcctc tcgaaggact ccagtgtgaa tcacactctg gaatacaatc 5100
gagcaagaca gtagaggtga gagcaggatt atacgtttac cccagggctc agtctgagtg 5160
acagcaggga cgctccctgg agagggagct gcagagcaag gtcccaagta cggctgtgct 5220
gtttcccagg agcagagagg gtgaggttcc aggacgggcc atccagaagt gctttatggt 5280
gtgcggacag tctctggcac ttcccgagga gtccacagtt ctgagactca ttttcttcag 5340
tgaagaagat tagataaggt tcccaagaaa ctcccggtgg acagccatgc tgtgtgaagc 5400
tttccttata gccagtctga gaactccgtc ttgccaggtc aacttttttt tttttttttt 5460
tttttttttg agacagggtt tctctgtgta gccctggctg tcctggaact cactctgtag 5520
accaggctgg cctcgaactc agaaacccgc cttcctctgc ctcccaagtg ctgggattaa 5580
aggcgtgcgc caccatgccc agcccaggtc agctttttgt tgtttgtttt taagtgttgg 5640
gcatccaacc tagggctttg agccatgagg cgcgtggtgc gcaactgagt tccactccca 5700
cccccacttc cagccctgaa cgtgcgcatg cgcgtaaagc aaactaaaac tcccaaggta 5760
tggttgaggg gaagatctga gggagagtac agccggaggc atccggagga gtccggagca 5820
gggaaagtag tagatggaca tggctagcag actggaccag gccaagaaga gaggagatag 5880
agagtgagga agacacaaga ggcccaagaa agcgcatagc ccaaatgtca cgactaccta 5940
cctacctacc aggatgagaa gctgggggcc agaaatcact ggaagccaat gagctggagg 6000
tgaggtgaag tttaggatcg ggtgagctga gctgagggga gctacaggtc ctgagtgggc 6060
ctgagtgggc ctggaggcca cagacacttg gtatgctaat aggcaccaca gttaagccat 6120
ttgtcctgag tctcttttgt atctgagaac cctgatagct ttcctcttcc acatgtggtt 6180
aggttctttc taacctggtc ccttggcgtc cctctcttaa atggatgttt agattgtgag 6240
aataggaacc cagtggagga agagaatatt ctttctggtt cctccggaga tgtgagagct 6300
ggtgagagga agatgtgtta ggcagaataa tgtcctttaa acgatgtcca ggcactgatc 6360
cccggacacc ttagggatat gtgatctgac agaaggggct ttgctggtat gactgagttg 6420
aagatcctga cggggagctg actggattct accctacgtg gactcacggt cattaacagg 6480
gtcctggaaa gatagagtaa gaaagagaac cagagggagg gtaacacaag gctgactggg 6540
cccagcattg acagagaaaa gggccacaag ccaaagaatg ccaatagctt ccagagcaca 6600
gaaaagggag atgccctggc gactccagaa ggaacaagcc ccacccccgc taccatctcc 6660
accctaggcc tgcttcacac acctgacctc aaagggatga taagtgataa atgtcgtgaa 6720
ataattgaga tgatatgtct ccgttggtaa aagctcttgc gtttggggga tgtgctacag 6780
cgctggcaga aactcaatgt gggcaggaaa cgctgctgtc tctgagattt gttgatgggt 6840
gcctgacttc cctggcttct gccaaaccca cagcaagctg accgcgcctg ccctccgcct 6900
tgctgctttg cccccctccc cgtcccgttc ccctgaggcc tgtgtgaatg aatggtctgc 6960
agtggggggg gggggggtgc tggaggcgcc tccgcaccct tcttctgact tggaggggct 7020
ctctgaaaac gtggtttggt ttgtgtttcc tgctttgctt tctggagccg catgtcttcc 7080
ttcccacctc tgaatgtttc tcgttaatct tcccatcaga gaaagtgtta cgacgatttc 7140
tcttttgagg gaaggttcca atgttttcag tctctagccc agcccacccg atatctgcct 7200
gtggcgatgg ttggaactgg tctcattggg gaatctgcta cccccacccc cacccccggg 7260
aatgtgttct tttgtgattt gtggctctca ggggtgggag acaagttaaa attgaacatt 7320
tcctcagtgg cttcgaacct gggatgcaga aagttatccg gatcccagcg atggaatgct 7380
gagagttttt gaggagcaaa tgatgtctga tcttgcccac atagcaaggg cctttgggag 7440
ttgactgact gattttgggc atctgcatga acacatacat gcagggtcat cttggtactc 7500
tctctgggct tagcaggtgc tcactctatg gggtggtctg ttattggtta ggattagggt 7560
tattcctgta gaaagatgga atcttgggca gctcacagtc aagtgccaca tatgatagat 7620
gggggaaccc agagtagtct agcctgtggt ccccacgacc tagagggtga cctaaaaaaa 7680
aatgtctccc atagtgccct cctcacaatc aggcccagga gggggtgagt ctgggagatc 7740
agctgctctt gttccagagc caaactgcag ccagagctgt gttgaataaa tgactttgac 7800
aacaggcacg gaaacattgt tgtaattctc tcaatttttc cccctctcct ctgccccttt 7860
tcctcctctt gttccctgtt cctcccaaga ctcgttttcc cagcttgcgg cccctctgaa 7920
cccaaggctt cacctgtaca atgatgagca gattctaact tgggagccgt caccttccag 7980
caatgaccca agaccagtgg tctaccaggt ggaatatagc ttgtaagtct gatgctctgc 8040
gggtgtcctt gatgctctgc aggagtcctt gatgttcagt gagtgtcctt gctgggtgag 8100
acctgttggg gaagttggct gggagcctgc agtgagatcc tgaccccggg ctttcagcat 8160
gactatggtg agacccccta tgcacacaaa agcttcaagg acagagatct catcacctcc 8220
tgctcatctg aggcgaactt aagcctggct gttaaagagc tgtggctgct gggacctcct 8280
ttattggtga cacatgatcc ctttgctctg tacagagtga gggttctctt ctgccctgga 8340
aaggcaagag atagctttca ggtttataac ctcaaagtcc aaactgagcc tactgaggaa 8400
tgtgttcagc agactacagt gaactctcag tttctcacct ggttttctgt tctgaataat 8460
ctagtgttca cgccctttgt gctgcctctc gcctcagtcg caggccacca cttgatttgc 8520
aaagccgtat tcactaagaa actgctcagt caaacggttt tgttttgttt tgttttgttt 8580
tcttggtcac atatgttagt tgaagatcaa gctgaaagca ctgggcacac ggttataaac 8640
aaaaactgat tgttttgaga tgagcattcc tgtttggctc agatagctct ggagctagag 8700
atcctcctgc ttcggcctcc aggaggagct gagactcctg ccagcccgcc agtgtcactg 8760
cactctgagc tttgtttaaa agacttccac agagctttgt attacagact cacttctttg 8820
actctagggt tggttgtttg tggggtgggt gggtgtgtgc acatgtgtgc gcaagcctct 8880
ctcacacaca tacacacatg cacgttcaca tacgcacaca gctgtgtgga agccagggag 8940
catggcaaag tgccttcctt agtcccgctc cccgtatttt tggggacggt ctctcactga 9000
acccagagct ctccaattca gctagattgg cagaccaggg aatcatcggg tttctcctct 9060
ccacgcctgc cccacccctc tccacgcctg ccccacccct ctccacgcct gccccacccc 9120
tctccacacc tgaacgctgc cggggtcact ggggttttgc aggtttgctt ggatgctgag 9180
ggtctgagcc caggctgaca gtttaacagt agccatttcc ccagctccct tgctttcttt 9240
cttcttagta aacattttgt atctttttta tcaggggttg aggttggttt tagtaagaaa 9300
agcattggta aacactaaag caggctggtc ccccaccctc actccctctg ctgcagagct 9360
ccgctcttgt gaggggaaga ggtctctggt tttgtttgac tttaaaaatc agttttctta 9420
tttgaggttt tttttttttt taactgattt tgagactaag atttaaaaac tgtgtttgtc 9480
tgtggtcaag catgactgcc attgtaaagg aaggcgtccc cttagctttt tatgaaggtc 9540
acagtagcaa ggccaaatct ataggagagt ctaggttcgt gtcaggttag cagttaaaat 9600
ccaccatctc ggatggccag cgtgctctcg aacgcgcaac atattaggta acgtctgaaa 9660
gcacaagtcc agagtgaccc tgtgcaaagt gtagagagaa tctcgtctct tgcactgtgt 9720
ggaagcctca ccgtgtgcca agaaaaagcc gactgccttt tagcaagagg caggaagaaa 9780
tatgtggggt ggaagagggt agaactctgg gaattcatca gaggcactgg agataggagc 9840
cgtaaccagc cagccatgtg gccttcagaa ttgaataacc gggaactaaa caaacaggaa 9900
cgagctaaag cttgtggcct gggcatttag tcataattaa gtctccggac ggaaaagctg 9960
tggctacagc ctggaagccg ggtgactctc ctgattagta aaccttagac cgagttggtg 10020
gcgctcgatg aactgtacga ttgagccgtg ttcatttcat tgctcatcta aatgcagcca 10080
gaatcatctt atttttaccc tctgtacgca aagggactcc ttccctcaga acccccgtcc 10140
cataaatctg tcttacatga gggcacatag aaataaaaca cagaatttta aagttttaga 10200
ggaagaaaaa aaacccaacc cattcattct gtgtcttgaa tgtcacagag gaagtcacag 10260
agaccagggg ttcatgggtc tccatgtggg atggttccgt tccggctgag ggagcctgaa 10320
cctcagtcac tgccgctgac tgaggcttcc gggtgaagag aggtggagga gaatcactat 10380
taatggatac cagatggggg tttggagggg agggctaagt aagaacatat tttaaaaatc 10440
agtcacagcc aagcagtggt ggcgcatgcc tttaatccca gcactcggga ggcagaggca 10500
ggtggatttc tgagttcgag accagcctgg tctacagagt gagttccagg acagccagga 10560
ctacacagag aaaccctgtc tcagaaaaaa aaaaaaaaaa aatcggtcat actggtggtc 10620
tcctaacctt gtgcacaccc tgagagcatt ggatacttga gtaggcgcag cgtatgacct 10680
aatctagcca agagtttctg tatgtgacct ttgcccaaaa gatgaatgag taagcgggtc 10740
ctcgggagga gttaatgtct ctagagaaca gggttactcg cgaagagaga attctgtgag 10800
ctgagatctt gttttccctc ccagcatcga tggctcttgg cataggttgc tggagccgaa 10860
ctgtacggac atcacagaga caaagtgtga cttaacagga ggcggccgct tgaagctttt 10920
cccacaccca ttcacagtct tcctgtgvcg ggtgcgagcc aagcgaggga acctcacttc 10980
caagtgggtg gggctggagc catttcaaca ctatgagaat ggtaagagaa cgtgggaaga 11040
aagctttaca ggggccagag gggcaactca gccgtgcaga gcactctggc tcttgcagag 11100
gaccggagtt cagttcccag cacccacatt ggggtgctcc caactgtctg agactccagc 11160
tccaggcatc taaacgccct tctctggcct cctcacgcac ccacactcac acgcagataa 11220
ataaaataga cacaccttta aaaagaaatg tcagtcccag gttttctcta cgtgcttctt 11280
cattgatcag tacggaaccc accctaggcc ttggtcctgg accccatcct aatacaccag 11340
agacaaatgg tgaggttgtc agagaccact gacctcaggc tgatgctaaa gaatagggtt 11400
tgctgcacca ggctctgggc tctaaatctg accccacgcc agttacttta aacagtgttt 11460
aatgggaagg tagttacagc catatttttg tttcctttgc tatggtgctg gggagcaggg 11520
acctgatacc tccctcctag gcaggtgctg tactgctgag cccccatatg catgcgtgca 11580
tgcgttcgtg tgtgcgtgcg tgcatgtgcg cgcacacaca cacacacaca cacacacaca 11640
cacacatgct caaaattcaa gtataagaca acagatgtga ccgctgtcta catagtcaat 11700
tctgtagtaa gcagttagtg tttttggctg tgtttttttg tttgtttttt gttttttaag 11760
aagtataatc ctagccgggc gtggtggcgc acgcctttaa tcccagcatt tgggaggcag 11820
aggcaggtgg atctttgagt tcaaggccag cctggtctac agagtgagtt ccaggacagc 11880
cagggctaca cagagaaacc ctgtctcaaa aacaaacaaa caaacaaaca aacaaacaaa 11940
cgaagtataa tcctaggtag catggcagat tttattgtta tgtgttgtta tcacaacagc 12000
aaaatgtgat agaaaattta aaataaagct ggataaatta ataaataaat aaaagatccc 12060
ccaaataacc cagagccatt aaaatgccag cttatttaaa agtgagctgg gggataaggg 12120
tggcacacac ctttagttgc agaacttggg aggttgagac aggcagatgt ccatgagttc 12180
aaagccagcc tggtctacag agtgagttcc aagcaagaca gagccacaca ttgagagacc 12240
ttgtctcaaa aaatcaactg tagaggaaaa ctcaatgatg cggtaaatgt tatatcacac 12300
tgtcacttag tcctgtttac ctacctgtaa catgtctcgt gttccacgtg gacgtggtag 12360
actgggatcc tcgtatgagg cagagcaggc ggcgtctttt tccctcactt aacatcatac 12420
tctccagagc cacacacttc tgtgcaaatt tcaaaccttg cacatctttt ctaccctgaa 12480
tgaaaacttc gcctccagtt taagtttctg ttcttgtctc tctgggattc tgacgcctgc 12540
tgggattcta caagctttgc ttgcagtcaa acaactccca gctgagagac agcatctcag 12600
ctagaacaat cttgaatgcc ttgagcaaga ccaaaaaccc ttgcagagtg ctgcacggcc 12660
ctccctgatg ggaacggaaa caacttccat gtagccctga tagatcccgg ctcacagggc 12720
ctttcagcag ggccagtcct ggatgctagc tccctggtaa acctcctgtt cagaacgggc 12780
atctgagtgc agcccattgc gagtgtaagt gtgaacgtgt gtgtacacac agtgtacata 12840
cgtgtggtgt ttaataggca cacacagtgt atacgggtgc ctgtgtcact cacgtgaggt 12900
ctctgtgatt ctatttcagt tactgttgga cctccgaaaa acatctcggt gaccccagga 12960
aaaggttccc tcgtcataca cttctcccct ccctttgatg tgttccacgg ggcaactttt 13020
cagtatcttg tccactactg ggaaaagtca gaaacccaac aggaacaggt aaggcccctt 13080
ttcttctttg tttatggttt ttttctcttt agagtttttt tttttttttc attaagcctc 13140
atgaggtgtc cagaacgtca caaatcttaa tttctagtat agaaatttct cctgtaaaac 13200
taaagcctcg ggctggggag atggttcggt gggcacagcg tttgctatgt gatcccaaga 13260
agctgagttc actccctccg cacctctgta aagtccggca tgttggtgtt ctatctctta 13320
tctccgttat ttacagcccc tcagtcttgt taccatttgg ttgtgttcac tgtggatttg 13380
aggagtcact agaaaagcta gaagctgcat ggccccatct gtccctctgc ttgtctgtct 13440
gtctgtctgt ccgtctgacc tgtgtggctc tggtgctgtc tacacaggtt gaaggccctt 13500
tcaagagcaa ctccattgtg ctgggcaatc tgaagccata cagagtatat tgtttacaaa 13560
ctgaggcaca actgattttg aaaaacaaaa aaatccgacc acatgggctc ttgagcaatg 13620
tatcctgtca cgaaacaaca gcaaatggta ggacatacct tcatgtatcc attacctgct 13680
gcaaaaaagg cttctcctga agtggttagg atggcatgct gtggcatgtg gctggtggtc 13740
ggagaagaga ccggaagtgc ttacccgaca ggagaattat attgaggtct cagcagcaat 13800
ggctgtgtga ctaggctgag cagcagccac aacgcctggg accaggagta tgtcagattt 13860
gtggtcgtct tgtttcagat tttaaaatgt ttgcatatat atataaaatg aggtgtctta 13920
gggatgaatc ctaaatctga ccataaaatt cccttatgtt ttcatagaca ccttgcatgc 13980
atagcctgaa ggaggcttta tataatattt ttagtacact ggtatagaat tttttattgc 14040
attttttgct tacttaagtg gggggtttgt gtgcatgtgt gtgtgtgtgt gtgtgtgtgt 14100
gcacgcgtgt gtgtgggagc gtgcatgcat acatgtcatg tgagtacact tgagtggccg 14160
tcagaggaca ctctgtggta ttgtgacagg atagaggacg ttcacactgc cctctgctgt 14220
cacacatggg tcttcaggac aaaatgcagg cctgtcggtc ttagaggcag gcaacttcat 14280
ttgctgaacc atctcaccgc tccaattgca ccggggccca tcaggtgaat ttggatgtgg 14340
aattttccat ttgtggtatt atgacagggc agtttttgat ttttgaatag aaattttcag 14400
gttttacatg ttcaggtcaa aattattagt ttaagcgcat attgaggcaa gggggtagag 14460
agggcctgtg ggtcttcctg ggacgagaaa acggcccagc agtgggagat ggggcgtgga 14520
ctgctgctgg cggcttgctc acttctgtgt catcttcttt agcctccgcc aggctgcagc 14580
aagtcatcct gattccgttg ggcatcttcg cattgctgct cggcctgacg ggcgcctgct 14640
tcaccctgtt cctcaaatac caaagccgag tgaagtactg gtttcaggct ccgccaaaca 14700
tcccggaaca aatcgaagag gtcagtgcgc agatgcgcga gtgacccgct gtggccccgc 14760
cccctcgtgg taggcgagaa tggacacccc gtgccgtcct ctgccccccc cgcccccgtg 14820
cgtgggcaca tgcccaccca catacgttca cacagaataa ctaagtagta aaatggctgt 14880
tgggttaggt cagagtctat ataacacgtg gctcgtggtg atgggttaaa ggtttccctt 14940
gttgacactg ccaaagagta acagttcccg atggcccttg agctttcact gggctcgtcc 15000
tgactctcag gtacagccct cagaggaact gagcctgggc caccacagtt gtttctctgg 15060
ggcagaaatc taaggttttg ctgtactttc ttgggaaagt gtgaagaact gccagaggct 15120
gctgacgtta cttgagagta gagattggtt tccgcttctg tgtctgaggt ttcacatggc 15180
acgcacatga cttctgttcc tctttccatt ggccgatagc acttctaaga gctgcggatg 15240
gagccctgga atcctggggg gtttatagcc aagagcaaaa gggaaagaaa gttcagggct 15300
gtgagacccc tcttcactgt gaggatccta gccccaccca gatgcgtcca gggttgtgtg 15360
caggtggaag gaggggctag agtttaggga cgttccctgc tttatcctgc cacagctggg 15420
cacagtgggg attcccactt ttcctgagtt ctgcccttcc cagctttcat cagatgaaca 15480
gaggatggag cccaggccct tgtactttct agacaagcgc tcttgctctg agctacacct 15540
gggcctgcgc cattacagag atgagggctg aagaggcagg cacgtgctgg aaatcagggc 15600
tgagcatgag ttagcagcag tgtgccctta ccgtgtgcca ggcctgggct tgacccctag 15660
ggtcacaaca gttaacaatg acgattggtg gtggtatcac ttcattgatg gacaaagtgg 15720
agttgtacct gattataata tgactacatc aactacaagt agggacattg tatcggactg 15780
tctgtaactg gctggccttc tatccttttc tagtatctaa aggacccaga ccaattcatc 15840
ttagaggtct tggacaagga cggttcaccg aaggaggact cctgggactc cgtgtcaatt 15900
atttcttctc cagaaaagga gcgagatgat gtgctccaaa caccgtgaac caggccaggg 15960
tctctgcttg cccaggaggg cagcgatcag tgcacccgag agagatcccc agggccccag 16020
gactggggaa gatggtgtag tgtttgttct ttatgagttt tctggatgct acaagtattt 16080
aaaaggattc cacagaaaga tatctcagaa acaaaacaaa aacaaaaaca aaccaagcgc 16140
ttctcttaaa cactaaaaag acaactgctc attactggca acgtggcggc aaacctgtgt 16200
gtggtgcttt ctccagtgtt agctgcccct gctgtcagaa gactgggtcc ttccttgcct 16260
tcactctgga aaatgagttg tcccagccaa ccctgcctgt cacaaagagg ggcccttagt 16320
gtccccttca tgtccaatgt gatggcttaa atgtgagacc cctgggctcg gtgcttgcct 16380
agcacgtaca cgccccaccc accccagcac ctcactcaca gagaggtgat taatcttgta 16440
aataatgtcc tggtaattta agtctttttt tttttttttt aatctagaga taaaagattg 16500
tatgttaaac tttttttttt tttaagtcta tctgccgggt ggtggtggtg cacaccttta 16560
ctcctggcac ttgggaggca gaggcaggag gatctctgtg agttcgaggc cagcctggtc 16620
tagagtcctg gtctaggaca gccaaggcta cacagagaaa ccctgtctgg taaacaaaac 16680
aggaaaaaga agtgcacgtg tttcttcttt tcttgtccct taccacgtcg ccttctttgc 16740
ctgttttccg taaagtattg acttgtgaaa agtcttagcc aggcatggtg acacatgcct 16800
ttattcccag cacttgaaag cagaggccag tagatttctg tgagtttgag gccagcctgg 16860
tctacatagt gagttccagg acagccaggg ctatgtagag agatcctggc tctctaaata 16920
aataataaat aaataccaaa cttaaaaata 16950
<210>2
<211>8951
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>2
aggtacccgt tacataactt acggtaaatg gcccgcctgg ctgaccgccc aacgaccccc 60
gcccattgac gtcaatagta acgccaatag ggactttcca ttgacgtcaa tgggtggagt 120
atttacggta aactgcccac ttggcagtac atcaagtgta tcatatgcca agtacgcccc 180
ctattgacgt caatgacggt aaatggcccg cctggcattg tgcccagtac atgaccttat 240
gggactttcc tacttggcag tacatctacg tattagtcat cgctattacc atggtcgagg 300
tgagccccac gttctgcttc actctcccca tctccccccc ctccccaccc ccaattttgt 360
atttatttat tttttaatta ttttgtgcag cgatgggggc gggggggggg ggggggcgcg 420
cgccaggcgg ggcggggcgg ggcggggggc ggggcggggc gaggcggaga ggtgcggcgg 480
cagccaatca gagcggcgcg ctccgaaagt ttccttttat ggcgaggcgg cggcggcggc 540
ggccctataa aaagcgaagc gcgcggcggg cgggagtcgc tgcgcgctgc cttcgccccg 600
tgccccgctc cgccgccgcc tcgcgccgcc cgccccggct ctgactgacc gcgttactcc 660
cacaggtgag cgggcgggac ggcccttctc ctccgggctg taattagctg agcaagaggt 720
aagggtttaa gggatggttg gttggtgggg tattaatgtt taattacctg gagcacctgc 780
ctgaaatcac tttttttcag gttggaccgg tgccaccatg gactataagg accacgacgg 840
agactacaag gatcatgata ttgattacaa agacgatgac gataagatgg ccccaaagaa 900
gaagcggaag gtcggtatcc acggagtccc agcagccgac aagaagtaca gcatcggcct 960
ggacatcggc accaactctg tgggctgggc cgtgatcacc gacgagtaca aggtgcccag 1020
caagaaattc aaggtgctgg gcaacaccga ccggcacagc atcaagaaga acctgatcgg 1080
agccctgctg ttcgacagcg gcgaaacagc cgaggccacc cggctgaaga gaaccgccag 1140
aagaagatac accagacgga agaaccggat ctgctatctg caagagatct tcagcaacga 1200
gatggccaag gtggacgaca gcttcttcca cagactggaa gagtccttcc tggtggaaga 1260
ggataagaag cacgagcggc accccatctt cggcaacatc gtggacgagg tggcctacca 1320
cgagaagtac cccaccatct accacctgag aaagaaactg gtggacagca ccgacaaggc 1380
cgacctgcgg ctgatctatc tggccctggc ccacatgatc aagttccggg gccacttcct 1440
gatcgagggc gacctgaacc ccgacaacag cgacgtggac aagctgttca tccagctggt 1500
gcagacctac aaccagctgt tcgaggaaaa ccccatcaac gccagcggcg tggacgccaa 1560
ggccatcctg tctgccagac tgagcaagag cagacggctg gaaaatctga tcgcccagct 1620
gcccggcgag aagaagaatg gcctgttcgg aaacctgatt gccctgagcc tgggcctgac 1680
ccccaacttc aagagcaact tcgacctggc cgaggatgcc aaactgcagc tgagcaagga 1740
cacctacgac gacgacctgg acaacctgct ggcccagatc ggcgaccagt acgccgacct 1800
gtttctggcc gccaagaacc tgtccgacgc catcctgctg agcgacatcc tgagagtgaa 1860
caccgagatc accaaggccc ccctgagcgc ctctatgatc aagagatacg acgagcacca 1920
ccaggacctg accctgctga aagctctcgt gcggcagcag ctgcctgaga agtacaaaga 1980
gattttcttc gaccagagca agaacggcta cgccggctac attgacggcg gagccagcca 2040
ggaagagttc tacaagttca tcaagcccat cctggaaaag atggacggca ccgaggaact 2100
gctcgtgaag ctgaacagag aggacctgct gcggaagcag cggaccttcg acaacggcag 2160
catcccccac cagatccacc tgggagagct gcacgccatt ctgcggcggc aggaagattt 2220
ttacccattc ctgaaggaca accgggaaaa gatcgagaag atcctgacct tccgcatccc 2280
ctactacgtg ggccctctgg ccaggggaaa cagcagattc gcctggatga ccagaaagag 2340
cgaggaaacc atcaccccct ggaacttcga ggaagtggtg gacaagggcg cttccgccca 2400
gagcttcatc gagcggatga ccaacttcga taagaacctg cccaacgaga aggtgctgcc 2460
caagcacagc ctgctgtacg agtacttcac cgtgtataac gagctgacca aagtgaaata 2520
cgtgaccgag ggaatgagaa agcccgcctt cctgagcggc gagcagaaaa aggccatcgt 2580
ggacctgctg ttcaagacca accggaaagt gaccgtgaag cagctgaaag aggactactt 2640
caagaaaatc gagtgcttcg actccgtgga aatctccggc gtggaagatc ggttcaacgc 2700
ctccctgggc acataccacg atctgctgaa aattatcaag gacaaggact tcctggacaa 2760
tgaggaaaac gaggacattc tggaagatat cgtgctgacc ctgacactgt ttgaggacag 2820
agagatgatc gaggaacggc tgaaaaccta tgcccacctg ttcgacgaca aagtgatgaa 2880
gcagctgaag cggcggagat acaccggctg gggcaggctg agccggaagc tgatcaacgg 2940
catccgggac aagcagtccg gcaagacaat cctggatttc ctgaagtccg acggcttcgc 3000
caacagaaac ttcatgcagc tgatccacga cgacagcctg acctttaaag aggacatcca 3060
gaaagcccag gtgtccggcc agggcgatag cctgcacgag cacattgcca atctggccgg 3120
cagccccgcc attaagaagg gcatcctgca gacagtgaag gtggtggacg agctcgtgaa 3180
agtgatgggc cggcacaagc ccgagaacat cgtgatcgaa atggccagag agaaccagac 3240
cacccagaag ggacagaaga acagccgcga gagaatgaag cggatcgaag agggcatcaa 3300
agagctgggc agccagatcc tgaaagaaca ccccgtggaa aacacccagc tgcagaacga 3360
gaagctgtac ctgtactacc tgcagaatgg gcgggatatg tacgtggacc aggaactgga 3420
catcaaccgg ctgtccgact acgatgtgga ccatatcgtg cctcagagct ttctgaagga 3480
cgactccatc gacaacaagg tgctgaccag aagcgacaag aaccggggca agagcgacaa 3540
cgtgccctcc gaagaggtcg tgaagaagat gaagaactac tggcggcagc tgctgaacgc 3600
caagctgatt acccagagaa agttcgacaa tctgaccaag gccgagagag gcggcctgag 3660
cgaactggat aaggccggct tcatcaagag acagctggtg gaaacccggc agatcacaaa 3720
gcacgtggca cagatcctgg actcccggat gaacactaag tacgacgaga atgacaagct 3780
gatccgggaa gtgaaagtga tcaccctgaa gtccaagctg gtgtccgatt tccggaagga 3840
tttccagttt tacaaagtgc gcgagatcaa caactaccac cacgcccacg acgcctacct 3900
gaacgccgtc gtgggaaccg ccctgatcaa aaagtaccct aagctggaaa gcgagttcgt3960
gtacggcgac tacaaggtgt acgacgtgcg gaagatgatc gccaagagcg agcaggaaat 4020
cggcaaggct accgccaagt acttcttcta cagcaacatc atgaactttt tcaagaccga 4080
gattaccctg gccaacggcg agatccggaa gcggcctctg atcgagacaa acggcgaaac 4140
cggggagatc gtgtgggata agggccggga ttttgccacc gtgcggaaag tgctgagcat 4200
gccccaagtg aatatcgtga aaaagaccga ggtgcagaca ggcggcttca gcaaagagtc 4260
tatcctgccc aagaggaaca gcgataagct gatcgccaga aagaaggact gggaccctaa 4320
gaagtacggc ggcttcgaca gccccaccgt ggcctattct gtgctggtgg tggccaaagt 4380
ggaaaagggc aagtccaaga aactgaagag tgtgaaagag ctgctgggga tcaccatcat 4440
ggaaagaagc agcttcgaga agaatcccat cgactttctg gaagccaagg gctacaaaga 4500
agtgaaaaag gacctgatca tcaagctgcc taagtactcc ctgttcgagc tggaaaacgg 4560
ccggaagaga atgctggcct ctgccggcga actgcagaag ggaaacgaac tggccctgcc 4620
ctccaaatat gtgaacttcc tgtacctggc cagccactat gagaagctga agggctcccc 4680
cgaggataat gagcagaaac agctgtttgt ggaacagcac aagcactacc tggacgagat 4740
catcgagcag atcagcgagt tctccaagag agtgatcctg gccgacgcta atctggacaa 4800
agtgctgtcc gcctacaaca agcaccggga taagcccatc agagagcagg ccgagaatat 4860
catccacctg tttaccctga ccaatctggg agcccctgcc gccttcaagt actttgacac 4920
caccatcgac cggaagaggt acaccagcac caaagaggtg ctggacgcca ccctgatcca 4980
ccagagcatc accggcctgt acgagacacg gatcgacctg tctcagctgg gaggcgacaa 5040
aaggccggcg gccacgaaaa aggccggcca ggcaaaaaag aaaaagtaag aattcctaga 5100
gctcgctgat cagcctcgac tgtgccttct agttgccagc catctgttgt ttgcccctcc 5160
cccgtgcctt ccttgaccct ggaaggtgcc actcccactg tcctttccta ataaaatgag 5220
gaaattgcat cgcattgtct gagtaggtgt cattctattc tggggggtgg ggtggggcag 5280
gacagcaagg gggaggattg ggaagagaat agcaggcatg ctggggagcg gccgcaggaa 5340
cccctagtga tggagttggc cactccctct ctgcgcgctc gctcgctcac tgaggccggg 5400
cgaccaaagg tcgcccgacg cccgggcttt gcccgggcgg cctcagtgag cgagcgagcg 5460
cgcagctgcc tgcaggggcg cctgatgcgg tattttctcc ttacgcatct gtgcggtatt 5520
tcacaccgca tacgtcaaag caaccatagt acgcgccctg tagcggcgca ttaagcgcgg 5580
cgggtgtggt ggttacgcgc agcgtgaccg ctacacttgc cagcgcctta gcgcccgctc 5640
ctttcgcttt cttcccttcc tttctcgcca cgttcgccgg ctttccccgt caagctctaa 5700
atcgggggct ccctttaggg ttccgattta gtgctttacg gcacctcgac cccaaaaaac 5760
ttgatttggg tgatggttca cgtagtgggc catcgccctg atagacggtt tttcgccctt 5820
tgacgttgga gtccacgttc tttaatagtg gactcttgtt ccaaactgga acaacactca 5880
actctatctc gggctattct tttgatttat aagggatttt gccgatttcg gtctattggt 5940
taaaaaatga gctgatttaa caaaaattta acgcgaattt taacaaaata ttaacgttta 6000
caattttatg gtgcactctc agtacaatct gctctgatgc cgcatagtta agccagcccc 6060
gacacccgcc aacacccgct gacgcgccct gacgggcttg tctgctcccg gcatccgctt 6120
acagacaagc tgtgaccgtc tccgggagct gcatgtgtca gaggttttca ccgtcatcac 6180
cgaaacgcgc gagacgaaag ggcctcgtga tacgcctatt tttataggtt aatgtcatga 6240
taataatggt ttcttagacg tcaggtggca cttttcgggg aaatgtgcgc ggaaccccta 6300
tttgtttatt tttctaaata cattcaaata tgtatccgct catgagacaa taaccctgat 6360
aaatgcttca ataatattga aaaaggaaga gtatgagtat tcaacatttc cgtgtcgccc 6420
ttattccctt ttttgcggca ttttgccttc ctgtttttgc tcacccagaa acgctggtga 6480
aagtaaaaga tgctgaagat cagttgggtg cacgagtggg ttacatcgaa ctggatctca 6540
acagcggtaa gatccttgag agttttcgcc ccgaagaacg ttttccaatg atgagcactt 6600
ttaaagttct gctatgtggc gcggtattat cccgtattga cgccgggcaa gagcaactcg 6660
gtcgccgcat acactattct cagaatgact tggttgagta ctcaccagtc acagaaaagc 6720
atcttacgga tggcatgaca gtaagagaat tatgcagtgc tgccataacc atgagtgata 6780
acactgcggc caacttactt ctgacaacga tcggaggacc gaaggagcta accgcttttt 6840
tgcacaacat gggggatcat gtaactcgcc ttgatcgttg ggaaccggag ctgaatgaag 6900
ccataccaaa cgacgagcgt gacaccacga tgcctgtagc aatggcaaca acgttgcgca 6960
aactattaac tggcgaacta cttactctag cttcccggca acaattaata gactggatgg 7020
aggcggataa agttgcagga ccacttctgc gctcggccct tccggctggc tggtttattg 7080
ctgataaatc tggagccggt gagcgtggaa gccgcggtat cattgcagca ctggggccag 7140
atggtaagcc ctcccgtatc gtagttatct acacgacggg gagtcaggca actatggatg 7200
aacgaaatag acagatcgct gagataggtg cctcactgat taagcattgg taactgtcag 7260
accaagttta ctcatatata ctttagattg atttaaaact tcatttttaa tttaaaagga 7320
tctaggtgaa gatccttttt gataatctca tgaccaaaat cccttaacgt gagttttcgt 7380
tccactgagc gtcagacccc gtagaaaaga tcaaaggatc ttcttgagat cctttttttc 7440
tgcgcgtaat ctgctgcttg caaacaaaaa aaccaccgct accagcggtg gtttgtttgc 7500
cggatcaaga gctaccaact ctttttccga aggtaactgg cttcagcaga gcgcagatac 7560
caaatactgt tcttctagtg tagccgtagt taggccacca cttcaagaac tctgtagcac 7620
cgcctacata cctcgctctg ctaatcctgt taccagtggc tgctgccagt ggcgataagt 7680
cgtgtcttac cgggttggac tcaagacgat agttaccgga taaggcgcag cggtcgggct 7740
gaacgggggg ttcgtgcaca cagcccagct tggagcgaac gacctacacc gaactgagat 7800
acctacagcg tgagctatga gaaagcgcca cgcttcccga agggagaaag gcggacaggt 7860
atccggtaag cggcagggtc ggaacaggag agcgcacgag ggagcttcca gggggaaacg 7920
cctggtatct ttatagtcct gtcgggtttc gccacctctg acttgagcgt cgatttttgt 7980
gatgctcgtc aggggggcgg agcctatgga aaaacgccag caacgcggcc tttttacggt 8040
tcctggcctt ttgctggcct tttgctcaca tgtgagggcc tatttcccat gattccttca 8100
tatttgcata tacgatacaa ggctgttaga gagataattg gaattaattt gactgtaaac 8160
acaaagatat tagtacaaaa tacgtgacgt agaaagtaat aatttcttgg gtagtttgca 8220
gttttaaaat tatgttttaa aatggactat catatgctta ccgtaacttg aaagtatttc 8280
gatttcttgg ctttatatat cttgtggaaa ggacgaaaca ccgaataatt gacacggagt 8340
cccgttttag agctagaaat agcaagttaa aataaggcta gtccgttatc aacttgaaaa 8400
agtggcaccg agtcggtgct tttttgtttt agagctagaa atagcaagtt aaaataaggc 8460
tagtccgttt ttagcgcgtg cgccaattct gcagacaaat ggctctagag gcatgtgagg 8520
gcctatttcc catgattcct tcatatttgc atatacgata caaggctgtt agagagataa 8580
ttggaattaa tttgactgta aacacaaaga tattagtaca aaatacgtga cgtagaaagt 8640
aataatttct tgggtagttt gcagttttaa aattatgttt taaaatggac tatcatatgc 8700
ttaccgtaac ttgaaagtat ttcgatttct tggctttata tatcttgtgg aaaggacgaa 8760
acaccgcatc gtacgcgtac gtgttgtttt agagctagaa atagcaagtt aaaataaggc 8820
tagtccgtta tcaacttgaa aaagtggcac cgagtcggtg cttttttgtt ttagagctag 8880
aaatagcaag ttaaaataag gctasgtccg tttttagcgc gtgcgccaat tctgcagaca 8940
aatggctcta g 8951
<210>3
<211>25
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>3
caccgctggc ctggttcacg gtgtt 25
<210>4
<211>6032
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>4
ctcatgacca aaatccctta acgtgagtta cgcgcgcgtc gttccactga gcgtcagacc 60
ccgtagaaaa gatcaaagga tcttcttgag atcctttttt tctgcgcgta atctgctgct 120
tgcaaacaaa aaaaccaccg ctaccagcgg tggtttgttt gccggatcaa gagctaccaa 180
ctctttttcc gaaggtaact ggcttcagca gagcgcagat accaaatact gttcttctag 240
tgtagccgta gttagcccac cacttcaaga actctgtagc accgcctaca tacctcgctc 300
tgctaatcct gttaccagtg gctgctgcca gtggcgataa gtcgtgtctt accgggttgg 360
actcaagacg atagttaccg gataaggcgc agcggtcggg ctgaacgggg ggttcgtgca 420
cacagcccag cttggagcga acgacctaca ccgaactgag atacctacag cgtgagctat 480
gagaaagcgc cacgcttccc gaagggagaa aggcggacag gtatccggta agcggcaggg 540
tcggaacagg agagcgcacg agggagcttc cagggggaaa cgcctggtat ctttatagtc 600
ctgtcgggtt tcgccacctc tgacttgagc gtcgattttt gtgatgctcg tcaggggggc 660
ggagcctatg gaaaaacgcc agcaacgcgg cctttttacg gttcctggcc ttttgctggc 720
cttttgctca catgttcttt cctgcgttat cccctgattc tgtggataac cgtattaccg 780
cctttgagtg agctgatacc gctcgccgca gccgaacgac cgagcgcagc gagtcagtga 840
gcgaggaagc ggaaggcgag agtagggaac tgccaggcat caaactaagc agaaggcccc 900
tgacggatgg cctttttgcg tttctacaaa ctctttctgt gttgtaaaac gacggccagt 960
cttaagctcg ggccccctgg gcggttctga taacgagtaa tcgttaatcc gcaaataacg 1020
taaaaacccg cttcggcggg tttttttatg gggagagttt agggaaagag catttgtcag 1080
aatatttaag ggcgcctgtc actttgcttg atatatgaga attatttaac cttataaatg 1140
agaaaaaagc aacgcacttt aaataagata cgttgctttt tcgattgatg aacacctata 1200
attaaactat tcatctatta tttatgattt tttgtatata caatatttct agtttgttaa 1260
agagaattaa gaaaataaat ctcgaaaata ataaagggaa aatcagtttt tgatatcaaa 1320
attatacatg tcaacgataa tacaaaatat aatacaaact ataagatgtt atcagtattt 1380
attatcattt agaataaatt ttgtgtcgcc cttaattgtg agcggataac aattacgagc 1440
ttcatgcaca gtggcgttga cattgattat tgactagtta ttaatagtaa tcaattacgg 1500
ggtcattagt tcatagccca tatatggagt tccgcgttac atagcatcgt acgcgtacgt 1560
gtttggaccg aaggaggact cctgggacgg atccatggtg agcaagggcg aggagctgtt 1620
caccggggtg gtgcccatcc tggtcgagct ggacggcgac gtaaacggcc acaagttcag 1680
cgtgtccggc gagggcgagg gcgatgccac ctacggcaag ctgaccctga agttcatctg 1740
caccaccggc aagctgcccg tgccctggcc caccctcgtg accaccctga cctacggcgt 1800
gcagtgcttc agccgttacc ccgaccacat gaagcagcac gacttcttca agtccgccat 1860
gcccgaaggc tacgtccagg agcgcaccat cttcttcaag gacgacggca actacaagac 1920
ccgcgccgag gtgaagttcg agggcgacac cctggtgaac cgcatcgagc tgaagggcat 1980
cgacttcaag gaggacggca acatcctggg gcacaagctg gagtacaact acaacagcca 2040
caacgtctat atcatggccg acaagcagaa gaacggcatc aaggtgaact tcaagatccg 2100
ccacaacatc gaggacggca gcgtgcagct cgccgaccac taccagcaga acacccccat 2160
cggcgacggc cccgtgctgc tgcccgacaa ccactacctg agcacccagt ccgccctgag 2220
caaagacccc aacgagaagc gcgatcacat ggtcctgctg gagttcgtga ccgccgccgg 2280
gatcactctc ggcatggacg agctgtacaa gggaagcgga gagggcagag gaagtctgct 2340
aacatgcggt gacgtcgagg agaatcctgg acctatgacc gagtacaagc ccacggtgcg 2400
cctcgccacc cgcgacgacg tcccccgggc cgtacgcacc ctcgccgccg cgttcgccga 2460
ctaccccgcc acgcgccaca ccgtcgaccc ggaccgccac atcgagcggg tcaccgagct 2520
gcaagaactc ttcctcacgc gcgtcgggct cgacatcggc aaggtgtggg tcgcggacga 2580
cggcgccgcg gtggcggtct ggaccacgcc ggagagcgtc gaagcggggg cggtgttcgc 2640
cgagatcggc ccgcgcatgg ccgagttgag cggttcccgg ctggccgcgc agcaacagat 2700
ggaaggcctc ctggcgccgc accggcccaa ggagcccgcg tggttcctgg ccaccgtcgg 2760
cgtctcgccc gaccaccagg gcaagggtct gggcagcgcc gtcgtgctcc ccggagtgga 2820
ggcggccgag cgcgccgggg tgcccgcctt cctggagacc tccgcgcccc gcaacctccc 2880
cttctacgag cggctcggct tcaccgtcac cgccgacgtc gaggtgcccg aaggaccgcg 2940
cacctggtgc atgacccgca agcccggtgc ctgaactccg tgtcaattat ttctcaaaca 3000
cgtacgcgta cgatgctcta gaatgctgat gggctagcaa aatcagcctc gactgtgcct 3060
tctagttgcc agccatctgt tgtttgcccc tcccccgtgc cttccttgac cctggaaggt 3120
gccactccca ctgtcctttc ctaataaaat gaggaaattg catcacaaca ctcaacccta 3180
tctcggtcta ttcttttgat ttataaggga ttttgccgat ttcggcctat tggttaaaaa 3240
atgagctgat ttaacaaaaa tttaacgcga attaattctg tggaatgtgt gtcagttagg 3300
gtgtggaaag tccccaggct ccccagcagg cagaagtatg caaagcatgc atctcaatta 3360
gtcagcaacc aggtgtggaa agtccccagg ctccccagca ggcagaagta tgcaaagcat 3420
gcatctcaat tagtcagcaa ccatagtccc gcccctaact ccgcccatcc cgcccctaac 3480
tccgcccagt tccgcccatt ctccgcccca tggctgacta atttttttta tttatgcaga 3540
ggccgaggcc gcctctgcct ctgagctatt ccagaagtag tgaggaggct tttttggagg 3600
cctaggcttt tgcaaaaagc tcccgggagc ttgtatatcc attttcggat ctgatcagca 3660
cgtgatgaaa aagcctgaac tcaccgcgac gtctgtcgag aagtttctga tcgaaaagtt 3720
cgacagcgtt tccgacctga tgcagctctc ggagggcgaa gaatctcgtg ctttcagctt 3780
cgatgtagga gggcgtggat atgtcctgcg ggtaaatagc tgcgccgatg gtttctacaa 3840
agatcgttat gtttatcggc actttgcatc ggccgcgctc ccgattccgg aagtgcttga 3900
cattggggaa ttcagcgaga gcctgaccta ttgcatctcc cgccgtgcac agggtgtcac 3960
gttgcaagac ctgcctgaaa ccgaactgcc cgctgttctg cagccggtcg cggaggccat 4020
ggatgcgatc gctgcggccg atcttagcca gacgagcggg ttcggcccat tcggaccgca 4080
aggaatcggt caatacacta catggcgtga tttcatatgc gcgattgctg atccccatgt 4140
gtatcactgg caaactgtga tggacgacac cgtcagtgcg tccgtcgcgc aggctctcga 4200
tgagctgatg ctttgggccg aggactgccc cgaagtccgg cacctcgtgc acgcggattt 4260
cggctccaac aatgtcctga cggacaatgg ccgcataaca gcggtcattg actggagcga 4320
ggcgatgttc ggggattccc aatacgaggt cgccaacatc ttcttctgga ggccgtggtt 4380
ggcttgtatg gagcagcaga cgcgctactt cgagcggagg catccggagc ttgcaggatc 4440
gccgcggctc cgggcgtata tgctccgcat tggtcttgac caactctatc agagcttggt 4500
tgacggcaat ttcgatgatg cagcttgggc gcagggtcga tgcgacgcaa tcgtccgatc 4560
cggagccggg actgtcgggc gtacacaaat cgcccgcaga agcgcggccg tctggaccga 4620
tggctgtgta gaagtactcg ccgatagtgg aaaccgacgc cccagcactc gtccgagggc 4680
aaaggaatag cacgtgctac gagatttcga ttccaccgcc gccttctatg aaaggttggg 4740
cttcggaatc gttttccggg acgccggctg gatgatcctc cagcgcgggg atctcatgct 4800
ggagttcttc gcccacccca acttgtttat tgcagcttat aatggttaca aataaagcaa 4860
tagcatcaca aatttcacaa ataaagcatt tttttcactg cattctagtt gtggtttgtc 4920
caaactcatc aatgtatctt atcatgtctg tataccgtcg acctctagct agagcttggc 4980
gtaatcattg tcattaccaa tgcttaatca gtgaggcacc tatctcagcg atctgtctat 5040
ttcgttcatc catagttgcc tgactccccg tcgtgtagat aactacgata cgggagggct 5100
taccatctgg ccccagcgct gcgatgatac cgcgagaacc acgctcaccg gctccggatt 5160
tatcagcaat aaaccagcca gccggaaggg ccgagcgcag aagtggtcct gcaactttat 5220
ccgcctccat ccagtctatt aattgttgcc gggaagctag agtaagtagt tcgccagtta 5280
atagtttgcg caacgttgtt gccatcgcta caggcatcgt ggtgtcacgc tcgtcgtttg 5340
gtatggcttc attcagctcc ggttcccaac gatcaaggcg agttacatga tcccccatgt 5400
tgtgcaaaaa agcggttagc tccttcggtc ctccgatcgt tgtcagaagt aagttggccg 5460
cagtgttatc actcatggtt atggcagcac tgcataattc tcttactgtc atgccatccg 5520
taagatgctt ttctgtgact ggtgagtact caaccaagtc attctgagaa tagtgtatgc 5580
ggcgaccgag ttgctcttgc ccggcgtcaa tacgggataa taccgcgcca catagcagaa 5640
ctttaaaagt gctcatcatt ggaaaacgtt cttcggggcg aaaactctca aggatcttac 5700
cgctgttgag atccagttcg atgtaaccca ctcgtgcacc caactgatct tcagcatctt 5760
ttactttcac cagcgtttct gggtgagcaa aaacaggaag gcaaaatgcc gcaaaaaagg 5820
gaataagggc gacacggaaa tgttgaatac tcatattctt cctttttcaa tattattgaa 5880
gcatttatca gggttattgt ctcatgagcg gatacatatt tgaatgtatt tagaaaaata 5940
aacaaatagg ggtcagtgtt acaaccaatt aaccaattct gaacattatc gcgagcccat 6000
ttatacctga atatggctca taacacccct tg 6032
<210>5
<211>1427
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>5
cgagatgatg tgctccaaac aggatccatg gtgagcaagg gcgaggagct gttcaccggg 60
gtggtgccca tcctggtcga gctggacggc gacgtaaacg gccacaagtt cagcgtgtcc 120
ggcgagggcg agggcgatgc cacctacggc aagctgaccc tgaagttcat ctgcaccacc 180
ggcaagctgc ccgtgccctg gcccaccctc gtgaccaccc tgacctacgg cgtgcagtgc 240
ttcagccgtt accccgacca catgaagcag cacgacttct tcaagtccgc catgcccgaa 300
ggctacgtcc aggagcgcac catcttcttc aaggacgacg gcaactacaa gacccgcgcc 360
gaggtgaagt tcgagggcga caccctggtg aaccgcatcg agctgaaggg catcgacttc 420
aaggaggacg gcaacatcct ggggcacaag ctggagtaca actacaacag ccacaacgtc 480
tatatcatgg ccgacaagca gaagaacggc atcaaggtga acttcaagat ccgccacaac 540
atcgaggacg gcagcgtgca gctcgccgac cactaccagc agaacacccc catcggcgac 600
ggccccgtgc tgctgcccga caaccactac ctgagcaccc agtccgccct gagcaaagac 660
cccaacgaga agcgcgatca catggtcctg ctggagttcg tgaccgccgc cgggatcact 720
ctcggcatgg acgagctgta caagggaagc ggagagggca gaggaagtct gctaacatgc 780
ggtgacgtcg aggagaatcc tggacctatg accgagtaca agcccacggt gcgcctcgcc 840
acccgcgacg acgtcccccg ggccgtacgc accctcgccg ccgcgttcgc cgactacccc 900
gccacgcgcc acaccgtcga cccggaccgc cacatcgagc gggtcaccga gctgcaagaa 960
ctcttcctca cgcgcgtcgg gctcgacatc ggcaaggtgt gggtcgcgga cgacggcgcc 1020
gcggtggcgg tctggaccac gccggagagc gtcgaagcgg gggcggtgtt cgccgagatc 1080
ggcccgcgca tggccgagtt gagcggttcc cggctggccg cgcagcaaca gatggaaggc 1140
ctcctggcgc cgcaccggcc caaggagccc gcgtggttcc tggccaccgt cggcgtctcg 1200
cccgaccacc agggcaaggg tctgggcagc gccgtcgtgc tccccggagt ggaggcggcc 1260
gagcgcgccg gggtgcccgc cttcctggag acctccgcgc cccgcaacct ccccttctac 1320
gagcggctcg gcttcaccgt caccgccgac gtcgaggtgc ccgaaggacc gcgcacctgg 1380
tgcatgaccc gcaagcccgg tgcctgaacc gtgaaccagg ccagggt 1427

Claims (10)

1. A method of preparing a cell line comprising the steps of: performing gene editing on a B-16 melanoma cell by using a CRIS-PITCh system, inserting a coding gene of green fluorescent protein EGFP into the seventh exon end of IFNGR2 gene in the B-16 melanoma cell, and performing fusion expression on the coding gene of the green fluorescent protein EGFP and the IFNGR2 gene; the CRIS-PITCh system comprises a sgRNA expression cassette; the target sequence of the sgRNA is (a1) or (a2) as follows:
(a1) position 15881 and 15903 from the 5' end of SEQ ID NO. 1;
(a2) SEQ ID NO.1 at position 15936 and 15958 from the 5' end.
2. The method of claim 1, wherein: the CRIS-PITCh system comprises a carrier A and a carrier B; the vector A comprises a Cas9 expression cassette, an sgRNA expression cassette and a PITCh sgRNA expression cassette; the vector B comprises a donor fragment and homologous arms positioned at two ends of the donor fragment; the donor fragment is (b1) or (b2) as follows:
(b1) position 1595 and 2974 from the 5' end of SEQ ID NO. 4;
(b2) SEQ ID NO.5 positions 28 to 1407 from the 5' end.
3. The method of claim 2, wherein:
the homology arms at both ends of the donor fragment in (b1) are the upstream homology arm shown in position 1567-1586 from the 5 'end of SEQ ID NO.4 and the downstream homology arm shown in position 2975-2994 from the 5' end of SEQ ID NO. 4;
or, the homology arms at both ends of the donor fragment of (b2) are the upstream homology arm as shown in SEQ ID NO.5 from 1 to 20 at the 5 'end and the downstream homology arm as shown in SEQ ID NO.5 from 1408-1427 at the 5' end.
4. A cell line produced by the method of any one of claims 1 to 3.
5. The use of the cell line of claim 4 in the study of the function and expression regulation mechanism of the IFNGR2 gene.
6. Use of the cell line of claim 4 in the screening of drugs for targeting tumor immunity.
7. The sgRNA expression cassette or the CRIS-PITCh system of any one of claims 1 to 3.
8. Use of the sgRNA expression cassette of any one of claims 1 to 3 or the CRIS-PITCh system in the preparation of the cell line of claim 4.
9. The sgRNA expression cassette of any one of claims 1 to 3, or the CRIS-PITCh system, for use in drug screening for studying IFNGR2 gene function and expression regulation mechanism or targeted tumor immunity.
10. Use of the sgRNA expression cassette of any one of claims 1 to 3 or the CRIS-PITCh system in the preparation of a cell line for studying the function and expression regulation mechanism of the IFNGR2 gene or for drug screening for targeted tumor immunity.
CN202010332139.1A 2020-04-24 2020-04-24 Construction method of IFNGR2 gene melanoma B-16 cell line for stably expressing knock-in EGFP Pending CN111440774A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010332139.1A CN111440774A (en) 2020-04-24 2020-04-24 Construction method of IFNGR2 gene melanoma B-16 cell line for stably expressing knock-in EGFP

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010332139.1A CN111440774A (en) 2020-04-24 2020-04-24 Construction method of IFNGR2 gene melanoma B-16 cell line for stably expressing knock-in EGFP

Publications (1)

Publication Number Publication Date
CN111440774A true CN111440774A (en) 2020-07-24

Family

ID=71648354

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010332139.1A Pending CN111440774A (en) 2020-04-24 2020-04-24 Construction method of IFNGR2 gene melanoma B-16 cell line for stably expressing knock-in EGFP

Country Status (1)

Country Link
CN (1) CN111440774A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112062827A (en) * 2020-09-16 2020-12-11 军事科学院军事医学研究院生物医学分析中心 Application of CEP55 protein in regulation of cilia de-assembly and preparation of cilia-related disease model
CN115058451A (en) * 2022-06-23 2022-09-16 五邑大学 Double-reporting plasmid for homologous recombination and single base editing and construction method and application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103619413A (en) * 2011-05-16 2014-03-05 科学与工业研究会 Method to modulate pigmentation process in the melanocytes of skin
CN106834233A (en) * 2016-09-07 2017-06-13 金睿德生物医药科技(苏州)有限公司 A kind of preparation can the first method of the iPSCs of spike in real time sources nerve
CN109852586A (en) * 2018-11-20 2019-06-07 广东医科大学 A method of establishing colorectal cancer HK2 reporter gene cell line

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103619413A (en) * 2011-05-16 2014-03-05 科学与工业研究会 Method to modulate pigmentation process in the melanocytes of skin
CN106834233A (en) * 2016-09-07 2017-06-13 金睿德生物医药科技(苏州)有限公司 A kind of preparation can the first method of the iPSCs of spike in real time sources nerve
CN109852586A (en) * 2018-11-20 2019-06-07 广东医科大学 A method of establishing colorectal cancer HK2 reporter gene cell line

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
YOSHINORI KAWABE ET AL.: "Targeted knock-in of an scFv-Fc antibody gene into the hprt locus of Chinese hamster ovary cells using CRISPR/Cas9 and CRIS-PITCh systems", 《JOURNAL OF BIOSCIENCE AND BIOENGINEERING》 *
周士博等: "利用CRIS-PITCh***构建原位表达CEP290-EGFP的细胞系", 《科学技术与工程》 *
樊浩等: "稳定表达敲入增强绿色荧光蛋白标记的干扰素γ受体2基因Ifngr2的黑素瘤细胞系的构建与鉴定", 《中国药理学与毒理学杂志》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112062827A (en) * 2020-09-16 2020-12-11 军事科学院军事医学研究院生物医学分析中心 Application of CEP55 protein in regulation of cilia de-assembly and preparation of cilia-related disease model
CN115058451A (en) * 2022-06-23 2022-09-16 五邑大学 Double-reporting plasmid for homologous recombination and single base editing and construction method and application thereof

Similar Documents

Publication Publication Date Title
KR102267412B1 (en) Rna trnascription vector and uses thereof
CN108753824B (en) Viral vectors for the treatment of retinal dystrophy
CN108138171B (en) Method for preparing gene modified T cell for expressing chimeric antigen receptor
AU704408B2 (en) Method for selecting high-expressing host cells
US20030220274A1 (en) GLP-1 gene delivery for the treatment of type 2 diabetes
KR101949293B1 (en) Complement factor b analogs and their uses
JPH06501845A (en) Expression of human CMV glycoprotein-H using a baculovirus-insect cell expression system
IL165347A (en) Chimeric cd154 and nucleic acid molecule encoding it
KR102015116B1 (en) Extracellular vesicle isolated from recombinant microorganism comprising polynucleotide encoding target protein and use thereof
CN111440774A (en) Construction method of IFNGR2 gene melanoma B-16 cell line for stably expressing knock-in EGFP
WO1994023048A2 (en) Gibbon ape leukemia virus-based retroviral vectors
SG175682A1 (en) Selection of human monoclonal antibodies by mammalian cell display
WO1999016885A1 (en) Killer t cell receptor recognizing human immunodeficiency virus
CN108137664B (en) AAV-EPO for treatment of companion animals
US20220330533A1 (en) Systems and methods for batch cultivation of non-transgenic heterogametes
AU2023241362A1 (en) Chimeric opsin GPCR proteins
KR102510154B1 (en) Visceral adipose tissue macrophage-targeted gene/carrier complex for preventing or treating obesity-induced type II diabetes
CN113943749B (en) Method for improving homologous recombination efficiency based on CRISPR gene editing system
KR102570821B1 (en) Recombinant viral vector and pharmaceutical composition incluidng thereof
KR102047030B1 (en) Viral vector manufacture
KR102163667B1 (en) Composite containing gene and gene delivery system for prevent or treatment of inflammatory disease
KR101973007B1 (en) Recombinant transition vector for enhancement of foreign protein expression
KR101998168B1 (en) Composite containing gene and gene delivery system for prevent or treatment of rheumatoid arthritis
CN112831524B (en) Artificially modified recombinant adenovirus vector, virus packaged by same and application thereof
TW202302858A (en) Insulin gene therapy to treat diabetes

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20200724